Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Olivia Newton-John Cancer Research Institute
Jonsson Comprehensive Cancer Center
Imperial College London
M.D. Anderson Cancer Center
Advanced Accelerator Applications
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
University of Iowa
University Health Network, Toronto
University of Alberta
Crinetics Pharmaceuticals Inc.
Amgen
Advanced Accelerator Applications
Merck Sharp & Dohme LLC
ITM Solucin GmbH
University of California, San Francisco
University of Iowa
British Columbia Cancer Agency
Orano Med LLC
ITM Solucin GmbH
Instituto do Cancer do Estado de São Paulo
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Harbour BioMed (Guangzhou) Co. Ltd.
Melanoma and Skin Cancer Trials Limited
University Health Network, Toronto
Providence Health & Services
University Hospital, Basel, Switzerland
Peking University
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CHU de Quebec-Universite Laval
Société Française d'Endoscopie Digestive
University of Iowa